The conference program, running from July 12 to 15, features three oral presentations that anchor the company's scientific efforts. Central to the discussion is new evidence from the TRAILBLAZER-ALZ 2 long-term extension, which examines the durability of clinical benefits and safety profiles associated with Kisunla. Researchers will also address methodological questions regarding the use of external controls in clinical trials to ensure more rigorous evidence generation.

Beyond therapeutic trials, the company is positioning blood-based diagnostics as a scalable alternative to specialized amyloid PET imaging. Dr. Samantha Burnham is scheduled to present findings indicating that P-tau217 assays show strong performance in identifying Alzheimer’s pathology before the onset of cognitive symptoms. While these diagnostic tools are not currently indicated for asymptomatic patients, the data provides a foundation for more accessible, early-stage detection methods in clinical practice.